- Conditions
- Schizophrenia
- Interventions
- Placebo, RO4917838, Antipshychotics (Standard of Care)
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 629 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 27
- States / cities
- Little Rock, Arkansas • Anaheim, California • Cerritos, California + 23 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Schizophrenia
- Interventions
- Placebo, Bitopertin, Antipsychotics
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 625 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 27
- States / cities
- Costa Mesa, California • Escondido, California • Granada Hills, California + 24 more
- Conditions
- Schizophrenia
- Interventions
- SPD489
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 2
- States / cities
- Oklahoma City, Oklahoma • Philadelphia, Pennsylvania
- Conditions
- Schizophrenia
- Interventions
- SPD489 low dose range (40mg, 80mg, and 100mg), SPD489 high dose range (120mg, 140mg and 160mg), Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 4
- States / cities
- Miami Springs, Florida • O'Fallon, Missouri • Saint Charles, Missouri + 1 more
- Conditions
- Schizophrenia
- Interventions
- SPD489 40mg, SPD489 100mg, SPD489 160mg, Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Irving, Texas
- Conditions
- Schizophrenia
- Interventions
- Placebo, bitopertin [RO4917838]
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 624 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 21
- States / cities
- Carson, California • Oceanside, California • San Diego, California + 17 more
- Conditions
- Schizophrenia and Predominant Negative Symptoms
- Interventions
- SPD489 (lisdexamfetamine dimesylate), Placebo matching SPD489 (lisdexamfetamine dimesylate)
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 27
- States / cities
- Little Rock, Arkansas • Anaheim, California • Costa Mesa, California + 21 more